Pfizer Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Pfizer Inc in the second quarter 2026?
Pfizer Inc achieved a return on average equity (ROE) of 4.91 % in its second quarter 2026, which is below Pfizer Inc's average return on equity, which stands at 16.81%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 57 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1607 to 1636.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 28 2026) II. Quarter	(Mar 29 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 28 2025) III. Quarter	(Jun 29 2025) II. Quarter
Y / Y Equity Change	-3.95 %	-0.26 %	-1.95 %	0.58 %	-
Y / Y Net Income Change	-	-9.32 %	-	-20.63 %	6000 %
Net Income (TTM) in Millions	4,370	7,535	7,812	9,869	10,792
Return On Equity (TTM)	4.91 %	8.39 %	8.69 %	10.93 %	11.97 %
PFE's Total Ranking	# 1636	# 1607	# 1411	# 1178	# 979
Equity (TTM) in Millions	85,492	90,404	86,775	93,096	89,012
Seq. Equity Change	-5.43 %	4.18 %	-6.79 %	4.59 %	-1.79 %
Seq. Net Income Change	-	-	-	21.24 %	-1.51 %

Back to PFE Management Effectiveness >> PFE's 5 Years Annual ROE >> Compare PFE ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 58
Sector	# 168
Overall	# 1636

Return On Equity Statistics
High	Average	Low
38.13 %	16.81 %	-2.8 %
(Apr 01 2018)

News about Pfizer Inc Return on Equity ROE

Pfizer Showcases Innovations in Infectious Disease Research at IDWeek 2025 Amid Financial Pressures,

Pfizer Inc. (NYSE: PFE) is set to showcase its latest advancements in the realm of respiratory health and infectious disease research at the upcoming IDWeek 2025 congress, taking place from October 19-22, 2025, in Atlanta, Georgia. The company is gearing up to present data derived from a total of 46 abstracts that encompass both company-led studies and collaborations with various partners. These presentations will illuminate significant strides made in the prevention and treatment of infectious diseases, underscoring Pfizer’s ongoing commitment to innovation in healthcare.IDWeek is an annual event that brings together a wide array of healthcare professionals, researchers, and industry leaders from around the globe to exchange knowledge and insights on infectious diseases, including COVID-19, HIV, and other respiratory conditions. For Pfizer, IDWeek 2025 presents a vital platform to demonstrate its cutting-edge scientific progress and to foster collaborations with global health experts.

PFE Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	86,775	88,497	89,288	95,916	77,462
Y / Y Equity Change	-1.95 %	-0.89 %	-6.91 %	23.82 %	22.04 %
Net Income in Millions	7,812	8,062	2,158	31,407	22,025
Y / Y Net Income Change	-3.1 %	273.59 %	-93.13 %	42.6 %	128.19 %
Return On Equity	9 %	9.11 %	2.42 %	32.74 %	28.43 %

Back to PFE Management Effectiveness >> PFE's 5 Years Annual ROE >> Compare PFE ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 9 %, due to deterioration of net income.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PFE's' Return on Equity at Yahoo Finance
PFE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PFE's Competitors
Subscribers only: Roe for Pfizer Inc's Suppliers
Subscribers only: Return On Equity for PFE's Customers

Companies with similar Return On Equity at Jun 28 2026, within Healthcare Sector	ROE
National Healthcare Corp	13.11 %
Kewaunee Scientific Corporation	12.61 %
Protagonist Therapeutics inc	11.80 %
Entrada Therapeutics Inc	11.77 %
Haemonetics Corporation	11.66 %
Globus Medical Inc	11.59 %
Labcorp Holdings Inc	11.58 %
Tactile Systems Technology Inc	11.49 %
Nature s Sunshine Products inc	11.26 %
Penumbra Inc	11.09 %
Henry Schein Inc	10.88 %
Cadre Holdings inc	10.76 %
Medtronic Plc	10.64 %
Viemed Healthcare Inc	10.53 %
U S Physical Therapy Inc	10.50 %
The Pennant Group Inc	10.18 %
Amphastar Pharmaceuticals Inc	10.11 %
Align Technology inc	10.09 %
Ardent Health Inc	9.92 %
Edwards Lifesciences Corporation	9.65 %
Addus Homecare Corp	9.57 %
IMPACT BIOMEDICAL INC.	9.56 %
Teva Pharmaceutical Industries Limited	9.11 %
Merit Medical Systems Inc	9.07 %
Bio techne Corp	9.01 %
Utah Medical Products Inc	8.74 %
Vaso Corporation	8.65 %
Veracyte Inc	8.64 %
Corcept Therapeutics Inc	8.27 %
Integer Holdings Corporation	7.43 %

Date modified: 2026-09-12T06:19:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.